Cargando…
Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
The advent of genomics has led to the identification of specific “driver” mutations in oncogenic kinases, and the development of targeted small molecule inhibitors to block their tumor-driving functions. These specific inhibitors have been a clinical success, and often significantly prolong the live...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687582/ https://www.ncbi.nlm.nih.gov/pubmed/29152593 http://dx.doi.org/10.1038/s41698-017-0007-0 |